2.Perdigon, G, Fuller, R & Raya, R (2001) Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol 2, 27–42.
3.Kato, I (2000) Antitumor activity of lactic acid bacteria. In Probiotics 3: Immunomodulation by the Gut Microflora and Probiotics, pp. 115–138 [Fuller, R & Perdigon, G]. London: Kluwer Academic Publishers.
4.de Moreno de Leblanc, A & Perdigon, G (2004) Yogurt feeding inhibits promotion and progression of experimental colorectal cancer. Med Sci Monit 10, BR96–BR104.
5.Matar, C, Valdez, JC, Medina, M et al. (2001) Immunomodulating effects of milks fermented by Lactobacillus helveticus and its non-proteolytic variant. J Dairy Res 68, 601–609.
6.Kato, I, Yokokura, T & Mutai, M (1984) Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens. Microbiol Immunol 28, 209–217.
7.Hayashi, K & Ohwaki, M (1989) Antitumoor activity of Lactobacillus casei (LC 9018) in mice: T cell subset depletion. Biotherapy 3, 1568–1574.
8.de Moreno de LeBlanc, A & Perdigon, G (2005) Reduction of beta-glucuronidase and nitroreductase activity by yoghurt in a murine colon cancer model. Biocell 29, 15–24.
9.de Moreno de LeBlanc, A, Valdez, J & Perdigón, G (2004) Inflammatory immune response. Eur J Inflamm 2, 21–31.
10.Bogdan, C, Rollinghoff, M & Diefenbach, A (2000) The role of nitric oxide in innate immunity. Immunol Rev 173, 17–26.
11.Patton, EA, La Flamme, AC, Pedras-Vasoncelos, JA et al. (2002) Central role for interleukin-4 in regulating nitric oxide-mediated inhibition of T-cell proliferation and gamma interferon production in schistosomiasis. Infect Immun 70, 177–184.
12.Perdigon, G, de Moreno de LeBlanc, A, Valdez, J et al. (2002) Role of yoghurt in the prevention of colon cancer. Eur J Clin Nutr 56, Suppl. 3, S65–S68.
13.Langholz, E, Munkholm, P, Davidsen, M et al. (1992) Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103, 1444–1451.
14.Gillen, CD, Walmsley, RS, Prior, P et al. (1994) Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35, 1590–1592.
15.Linskens, RK, Huijsdens, XW, Savelkoul, PH et al. (2001) The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 36, 29–40.
16.de Moreno de LeBlanc, A, Chaves, S & Perdigón, G (2009) Effect of yoghurt on the cytokine profile using a murine model of intestinal inflammation. Eur J Inflamm 7, 97–109.
17.Rath, HC, Wilson, KH & Sartor, RB (1999) Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 67, 2969–2974.
18.Verdu, EF, Bercik, P, Cukrowska, B et al. (2000) Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol 120, 46–50.
19.Chandran, P, Satthaporn, S, Robins, A et al. (2003) Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). Surgeon 1, 63–75.
20.Videla, S, Vilaseca, J, Guarner, F et al. (1994) Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 35, 1090–1097.
21.Favier, C, Neut, C, Mizon, C et al. (1997) Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 42, 817–822.
22.Malin, M, Suomalainen, H, Saxelin, M et al. (1996) Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40, 137–145.
23.de Moreno de LeBlanc, A, Matar, C & Perdigon, G (2007) The application of probiotics in cancer. Br J Nutr 98, Suppl. 1, S105–S110.
24.Fuss, IJ, Neurath, M, Boirivant, M et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157, 1261–1270.
25.Dong, C (2006) Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6, 329–333.
26.Zhang, Z, Zheng, M, Bindas, J et al. (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12, 382–388.
27.Berg, DJ, Davidson, N, Kuhn, R et al. (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98, 1010–1020.
28.Singh, B, Read, S, Asseman, C et al. (2001) Control of intestinal inflammation by regulatory T cells. Immunol Rev 182, 190–200.
29.Brandtzaeg, P, Farstad, IN & Haraldsen, G (1999) Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 20, 267–277.
30.Brandtzaeg, P & Pabst, R (2004) Let's go mucosal: communication on slippery ground. Trends Immunol 25, 570–577.
31.de Moreno de LeBlanc, A, Maldonado Galdeano, C, Chaves, S et al. (2005) Oral administration of Lactobacillus casei CRL 431 increases immunity in bronchus and mammary glands. Eur J Inflamm 3, 23–28.
32.LeBlanc, JG, Matar, C, Valdez, JC et al. (2002) Immunomodulating effects of peptidic fractions issued from milk fermented with Lactobacillus helveticus. J Dairy Sci 85, 2733–2742.
33.Vinderola, CG, Duarte, J, Thangavel, D et al. (2005) Immunomodulating capacity of kefir. J Dairy Res 72, 195–202.
34.Furukawa, N, Matsuoka, A, Takahashi, T et al. (1990) Effects of orally administered yogurt and kefir on tumor growth in mice. J Jpn Soc Nutr Food Sci 43, 450–453.
35.Murofushi, M, Mizuguchi, J, Aibara, K et al. (1986) Immunopotentiative effect of polysaccharide from kefir grain, KGF-C, administered orally in mice. Immunopharmacology 12, 29–35.
36.de Moreno de LeBlanc, A, Matar, C, Farnworth, E et al. (2006) Study of cytokines involved in the prevention of a murine experimental breast cancer by kefir. Cytokine 34, 1–8.
37.Reome, JB, Hylind, JC, Dutton, RW et al. (2004) Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol 111, 69–81.
38.Zhang, G, Li, W, Holle, L et al. (2002) A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin Cancer Res 8, 1196–1205.
39.Reed, MJ & Purohit, A (1997) Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev 18, 701–715.
40.de Moreno de LeBlanc, A, Matar, C, LeBlanc, N et al. (2005) Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Res 7, 477–486.